BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 30643016)

  • 1. Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions.
    Cocco E; Benhamida J; Middha S; Zehir A; Mullaney K; Shia J; Yaeger R; Zhang L; Wong D; Villafania L; Nafa K; Scaltriti M; Drilon A; Saltz L; Schram AM; Stadler ZK; Hyman DM; Benayed R; Ladanyi M; Hechtman JF
    Cancer Res; 2019 Mar; 79(6):1047-1053. PubMed ID: 30643016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MLH1-deficient Colorectal Carcinoma With Wild-type BRAF and MLH1 Promoter Hypermethylation Harbor KRAS Mutations and Arise From Conventional Adenomas.
    Farchoukh L; Kuan SF; Dudley B; Brand R; Nikiforova M; Pai RK
    Am J Surg Pathol; 2016 Oct; 40(10):1390-9. PubMed ID: 27438990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MSI-High RAS-BRAF wild-type colorectal adenocarcinomas with MLH1 loss have a high frequency of targetable oncogenic gene fusions whose diagnoses are feasible using methods easy-to-implement in pathology laboratories.
    Bocciarelli C; Caumont C; Samaison L; Cariou M; Aline-Fardin A; Doucet L; Roudié J; Terris B; Merlio JP; Marcorelles P; Cappellen D; Uguen A
    Hum Pathol; 2021 Aug; 114():99-109. PubMed ID: 34019865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients.
    Ye JX; Liu Y; Qin Y; Zhong HH; Yi WN; Shi XY
    World J Gastroenterol; 2015 Feb; 21(5):1595-605. PubMed ID: 25663779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of somatic mutl homolog 1 promoter hypermethylation in Lynch syndrome colorectal cancer.
    Moreira L; Muñoz J; Cuatrecasas M; Quintanilla I; Leoz ML; Carballal S; Ocaña T; López-Cerón M; Pellise M; Castellví-Bel S; Jover R; Andreu M; Carracedo A; Xicola RM; Llor X; Boland CR; Goel A; Castells A; Balaguer F;
    Cancer; 2015 May; 121(9):1395-404. PubMed ID: 25557234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct BRAF (V600E) and KRAS mutations in high microsatellite instability sporadic colorectal cancer in African Americans.
    Kumar K; Brim H; Giardiello F; Smoot DT; Nouraie M; Lee EL; Ashktorab H
    Clin Cancer Res; 2009 Feb; 15(4):1155-61. PubMed ID: 19190129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct features between MLH1-methylated and unmethylated colorectal carcinomas with the CpG island methylator phenotype: implications in the serrated neoplasia pathway.
    Kim JH; Bae JM; Cho NY; Kang GH
    Oncotarget; 2016 Mar; 7(12):14095-111. PubMed ID: 26883113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive analysis of oncogenic fusions in mismatch repair deficient colorectal carcinomas by sequential DNA and RNA next generation sequencing.
    Wang J; Li R; Li J; Yi Y; Liu X; Chen J; Zhang H; Lu J; Li C; Wu H; Liang Z
    J Transl Med; 2021 Oct; 19(1):433. PubMed ID: 34657620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lynch syndrome-associated colorectal carcinoma: frequent involvement of the left colon and rectum and late-onset presentation supports a universal screening approach.
    Hartman DJ; Brand RE; Hu H; Bahary N; Dudley B; Chiosea SI; Nikiforova MN; Pai RK
    Hum Pathol; 2013 Nov; 44(11):2518-28. PubMed ID: 24034859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early onset MSI-H colon cancer with MLH1 promoter methylation, is there a genetic predisposition?
    van Roon EH; van Puijenbroek M; Middeldorp A; van Eijk R; de Meijer EJ; Erasmus D; Wouters KA; van Engeland M; Oosting J; Hes FJ; Tops CM; van Wezel T; Boer JM; Morreau H
    BMC Cancer; 2010 May; 10():180. PubMed ID: 20444249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumors.
    Lubomierski N; Plotz G; Wormek M; Engels K; Kriener S; Trojan J; Jungling B; Zeuzem S; Raedle J
    Cancer; 2005 Sep; 104(5):952-61. PubMed ID: 16015629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Annexin A10 expression correlates with serrated pathway features in colorectal carcinoma with microsatellite instability.
    Kim JH; Rhee YY; Kim KJ; Cho NY; Lee HS; Kang GH
    APMIS; 2014 Dec; 122(12):1187-95. PubMed ID: 24909058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microsatellite instability, MLH1 promoter methylation, and BRAF mutation analysis in sporadic colorectal cancers of different ethnic groups in Israel.
    Vilkin A; Niv Y; Nagasaka T; Morgenstern S; Levi Z; Fireman Z; Fuerst F; Goel A; Boland CR
    Cancer; 2009 Feb; 115(4):760-9. PubMed ID: 19127559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.
    Sinicrope FA; Shi Q; Smyrk TC; Thibodeau SN; Dienstmann R; Guinney J; Bot BM; Tejpar S; Delorenzi M; Goldberg RM; Mahoney M; Sargent DJ; Alberts SR
    Gastroenterology; 2015 Jan; 148(1):88-99. PubMed ID: 25305506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinction of hereditary nonpolyposis colorectal cancer and sporadic microsatellite-unstable colorectal cancer through quantification of MLH1 methylation by real-time PCR.
    Bettstetter M; Dechant S; Ruemmele P; Grabowski M; Keller G; Holinski-Feder E; Hartmann A; Hofstaedter F; Dietmaier W
    Clin Cancer Res; 2007 Jun; 13(11):3221-8. PubMed ID: 17545526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathologic features of synchronous colorectal carcinoma: A distinct subset arising from multiple sessile serrated adenomas and associated with high levels of microsatellite instability and favorable prognosis.
    Hu H; Chang DT; Nikiforova MN; Kuan SF; Pai RK
    Am J Surg Pathol; 2013 Nov; 37(11):1660-70. PubMed ID: 23887157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations of defect mismatch repair genes with prognosis and heredity in sporadic colorectal cancer.
    Ghanipour L; Jirström K; Sundström M; Glimelius B; Birgisson H
    Eur J Surg Oncol; 2017 Feb; 43(2):311-321. PubMed ID: 27836416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer.
    Capper D; Voigt A; Bozukova G; Ahadova A; Kickingereder P; von Deimling A; von Knebel Doeberitz M; Kloor M
    Int J Cancer; 2013 Oct; 133(7):1624-30. PubMed ID: 23553055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions.
    Singh H; Li YY; Spurr LF; Shinagare AB; Abhyankar R; Reilly E; Brais LK; Nag A; Ducar MD; Thorner AR; Shapiro GI; Keller RB; Siletti C; Clark JW; Farago AF; Lin JJ; Demetri GD; Gujrathi R; Kulke MH; MacConaill LE; Ligon AH; Sicinska E; Meyerson ML; Meyerhardt JA; Cherniack AD; Wolpin BM; Ng K; Giannakis M; Hornick JL; Cleary JM
    Clin Cancer Res; 2021 Mar; 27(6):1695-1705. PubMed ID: 33414136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant RASSF1A hypermethylation and KRAS/BRAF mutations occur preferentially in MSI sporadic colorectal cancer.
    Oliveira C; Velho S; Domingo E; Preto A; Hofstra RM; Hamelin R; Yamamoto H; Seruca R; Schwartz S
    Oncogene; 2005 Nov; 24(51):7630-4. PubMed ID: 16007118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.